Search

everythinglearnresearchcommunity

for

Search:↓

Minoxidil and finasteride effectively treat hair loss.

Finasteride effectively treats hair loss and enlarged prostate in men, with mild side effects.

Triple Hormonal Blockade (ADT3) can effectively manage prostate cancer but requires careful monitoring for heart risks.

Early hair loss may indicate prostate issues.

Enhancers and super-enhancers are key in controlling specific gene activity and can play a role in cancer development.

ERG increases SOX9, promoting prostate cancer growth and invasion.

Finasteride in male rats causes liver and metabolic issues in their offspring.

Decursin shows promise for treating cancer, neuroprotection, inflammation, and hair loss.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.

Testosterone supplements can increase muscle mass and strength in older men with low levels, but long-term effects and risks need more research.

The JAK/STAT pathway is important in cell processes and disease, and JAK inhibitors are promising for treating related conditions.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

Understanding how androgens work is key for creating new treatments for prostate issues and hair/skin conditions.

Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.

Finasteride treats hair loss but may cause side effects like low libido and dizziness.

5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.

Patients with metabolic syndrome had lower Gleason scores when diagnosed with prostate cancer.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

Low dose finasteride causes only small changes in PSA levels in older men with BPH.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Riboflavin 5′-phosphate (FMN) shows potential for treating androgen-related conditions but may be limited in treating prostate cancer.

Men with benign prostatic hyperplasia are more likely to have metabolic syndrome than those without it.

New treatments are making advanced prostate cancer management more complex but also more hopeful.

There's no link between hair loss type androgenic alopecia and benign prostatic hyperplasia, but early hair loss and family history can mean more severe alopecia.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

PSA screening's effectiveness in reducing prostate cancer deaths can vary based on trial design and participant compliance.

Finasteride reduces prostate size and PSA levels in young patients.